A novel recombinant protein of ephrinA1–PE38/GM-CSF activate dendritic cells vaccine in rats with glioma

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5497-5503

  Li, Ming ^a   Wang, Bin ^a   Wu, Zhonghua ^a   Zhang, Jiadong ^a   Shi, Xiwen ^a   Cheng, Wenlan ^a   Han, Shuangyin ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Dendritic cells; EphrinA1; Glioma; GM CSF

Indexed keywords

BACTERIAL TOXIN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; EPHRIN A1; EPITOPE; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PE 38; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RECOMBINANT PROTEIN; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ADENOVIRUS INFECTION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG POTENTIATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FLOW CYTOMETRY; GLIOMA; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SURVIVAL RATE; TUMOR ESCAPE; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; VACCINE PRODUCTION; ADENOVIRIDAE; ANIMAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETICS; HUMAN; IMMUNOLOGY;

ADENOVIRIDAE; ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, NEOPLASM; BACTERIAL TOXINS; CANCER VACCINES; DENDRITIC CELLS; EPHRIN-A1; EXOTOXINS; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; RATS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRULENCE FACTORS;

EID: 84938199690     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3217-5     Document Type: Article

References (33)

1. Folkman J. Angiogenesis in cancer vascular rheumatoid and other disease. Nat Med. 1995;1(1):27–31.
2. Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390(27):335–6.
3. Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol. 2006;15(3):175–86.
4. Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther. 2013;139(3):341–58.
5. Fan M, Liu Y, Xia F, Wang Z, Huang Y, Li J, et al. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma. Tumori. 2013;99(6):689–96.
6. Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, et al. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules. 2013;18(10):13043–60.
7. Chen H, Yuan B, Zheng Z, Liu Z, Wang S, Liu Y. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells. Cell Immunol. 2011;272(1):102–6.
8. Alho I, Costa L, Bicho M, Coelho C. Low molecular weight protein tyrosine phosphatase isoforms regulate breast cancer cells migration through a RhoA dependent mechanism. PLoS One. 2013;8(9):e76307.
9. Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013;12(4):267–74.
10. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087–101.
11. Mantripragada K, Khurshid H. Targeting genomic alterations in squamous cell lung cancer. Front Oncol. 2013;3(8):195.
12. Lee HY, Mohammed KA, Goldberg EP, Nasreen N. Arginine-conjugated albumin microspheres inhibits proliferation and migration in lung cancer cells. Am J Cancer Res. 2013;3(3):266–77.
13. Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol. 2013;42(6):2103–15.
14. Sun XL, Xu ZM, Ke YQ, Hu CC, Wang SY, Ling GQ, et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett. 2011;312(2):168–77.
15. Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Menard C, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res. 2007;67(3):851–3.
16. Kyte JA, Mu L, Aamdal S, Kvalheim G. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13(10):905–18.
17. Hu CC, Ke YQ, Sun XL, Jiang XD, Xu RX, Lv J, et al. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett. 2009;31(2):181–9.
18. Hu CC, Ji HM, Chen SL, Zhang HW, Wang BQ, Zhou LY, et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int J Cancer. 2010;127(9):2222–9.
19. Li M, Liu J, Zhang SZ, Zhou Y, Guo YW, Chen Q, et al. Cellular immunologic response to primary cryoablation of C6 gliomas in rats. Technol Cancer Res Treat. 2011;10(1):95–100.
20. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.
21. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161(3):777–82.
22. Wang H, Su X, Zhang P, Liang J, Wei H, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine. 2011;29(12):2328–35.
23. Debenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.
24. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A. 2000;97(6):2715–8.
25. Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity. 2010;33(5):699–712.
26. Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26(8):757–63.
27. Wertel I, Bednarek W, Stachowicz N, Rogala E, Nowicka A, Kotarski J. Phenotype of dendritic cells generated from peripheral blood monocytes of patients with ovarian cancer. Transplant Proc. 2010;42(8):3301–5.
28. Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010;62(8):611–7.
29. Lee JH, Roh MS, Lee YK, Kim MK, Han JY. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010;17(2):73–9.
30. Si T, Guo Z, Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. J Immunother. 2009;32(1):86–91.
31. Ward JE, Mcneel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7(12):1893–902.
32. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines. 2005;4(3):259–74.
33. Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008;44(4):271–8.